Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C16H22ClN3O2.ClH |
| Molecular Weight | 360.279 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.COC1=C(C=C(Cl)C(N)=C1)C(=O)N[C@@H]2CC[N@@]3CCC[C@H]2C3
InChI
InChIKey=WYONTPMGUQWRKN-WUCQATPYSA-N
InChI=1S/C16H22ClN3O2.ClH/c1-22-15-8-13(18)12(17)7-11(15)16(21)19-14-4-6-20-5-2-3-10(14)9-20;/h7-8,10,14H,2-6,9,18H2,1H3,(H,19,21);1H/t10?,14-;/m1./s1
| Molecular Formula | C16H22ClN3O2 |
| Molecular Weight | 323.818 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Renzapride (BRL-24924) is a mixed 5-hydroxytryptamine type 4 (5-HT4) agonist and 5-HT3 receptor antagonist. This compound has a stimulatory effect on gastrointestinal motility and transit. Renzapride has been evaluated for use in treatment of irritable bowel syndrome (IBS). Data also suggested a potentially beneficial effect on abdominal pain/discomfort in women with constipation-predominant irritable bowel syndrome. Phase III clinical trials investigated if this drug could help alleviate the symptoms associated with this type of IBS. However, one phase III study has been terminated due to inefficient efficacy (compared to placebo).
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| 5HT4(a) and 5-HT4(b) receptors have nearly identical pharmacology and are both expressed in human atrium and ventricle. | 2001-02 |
|
| Pharmacological characterization of the human 5-HT(4(d)) receptor splice variant stably expressed in Chinese hamster ovary cells. | 2000-10 |
|
| Isolation of the serotoninergic 5-HT4(e) receptor from human heart and comparative analysis of its pharmacological profile in C6-glial and CHO cell lines. | 2000-02 |
|
| Cloning, expression, and pharmacology of four human 5-hydroxytryptamine 4 receptor isoforms produced by alternative splicing in the carboxyl terminus. | 1998-06 |
|
| Cloning and expression of human 5-HT4S receptors. Effect of receptor density on their coupling to adenylyl cyclase. | 1997-10-20 |
|
| [3H]RS 57639, a high affinity, selective 5-HT4 receptor partial agonist, specifically labels guinea-pig striatal and rat cloned (5-HT4S and 5-HT4L) receptors. | 1997-04-01 |
|
| Cloning, expression and pharmacology of the mouse 5-HT(4L) receptor. | 1996-11-25 |
|
| [3H]5-hydroxytryptamine labels the agonist high affinity state of the cloned rat 5-HT4 receptor. | 1996-05-23 |
|
| The 5-HT4 receptor: molecular cloning and pharmacological characterization of two splice variants. | 1995-06-15 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:30:02 GMT 2025
by
admin
on
Mon Mar 31 21:30:02 GMT 2025
|
| Record UNII |
6H0SNK4GNT
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
300000001440
Created by
admin on Mon Mar 31 21:30:02 GMT 2025 , Edited by admin on Mon Mar 31 21:30:02 GMT 2025
|
PRIMARY | |||
|
DTXSID40911383
Created by
admin on Mon Mar 31 21:30:02 GMT 2025 , Edited by admin on Mon Mar 31 21:30:02 GMT 2025
|
PRIMARY | |||
|
109872-41-5
Created by
admin on Mon Mar 31 21:30:02 GMT 2025 , Edited by admin on Mon Mar 31 21:30:02 GMT 2025
|
PRIMARY | |||
|
20843171
Created by
admin on Mon Mar 31 21:30:02 GMT 2025 , Edited by admin on Mon Mar 31 21:30:02 GMT 2025
|
PRIMARY | |||
|
6H0SNK4GNT
Created by
admin on Mon Mar 31 21:30:02 GMT 2025 , Edited by admin on Mon Mar 31 21:30:02 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |